Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672831 | 0.86 | TP53 (0.54) | TP53MAPTSMN1; SMN2F2RL3NPC1 | |
| SCHEMBL12690055 | 0.83 | TP53 (0.40) | TP53MAPTSMN1; SMN2F2RL3NPC1 | |
| SCHEMBL20642850 | 0.80 | TP53 (0.37) | TP53MAPTSMN1; SMN2F2RL3NPC1 | |
| SCHEMBL1672605 | 0.71 | TP53 (0.40) | TP53MAPTSMN1; SMN2F2RL3NPC1 | |
| SCHEMBL1671683 | 0.69 | POLB (0.35) | MAPTPKMPOLB | |
| SCHEMBL1671679 | 0.66 | TP53 (0.58) | TP53MAPTSMN1; SMN2F2RL3NPC1 | |
| SCHEMBL21138063 | 0.65 | TP53 (0.65) | TP53MAPTSMN1; SMN2NPC1PKM | |
| SCHEMBL31597538 | 0.64 | TP53 (0.36) | TP53MAPTL3MBTL1 | |
| SCHEMBL13204686 | 0.64 | MEN1 (0.55) | MAPTNPC1RAB9A | |
| SCHEMBL1672156 | 0.63 | TP53 (0.54) | TP53MAPTSMN1; SMN2F2RL3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491045-B1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | EP | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2491045-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Pharma S.A. (BE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047860-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | CYP3A4, CYP3A43, CYP3A7 | TP53 2687/4885MAPT 1016/4885SMN1; SMN2 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.